IllnessPrenatal DSD, differential diagnosis
Summary
Comprehensive differential diagnostic panel for Prenatal DSD containing 35 core candidate genes and altogether >120 curated genes according to the clinical signs
| Locus type | Count |
|---|---|
| Gen | 106 |
228,3 kb (Extended panel: incl. additional genes)
- Amniotic fluid (after amnocentesis)
- Chorionic villus
- EDTA-anticoagulated blood (3-5 ml)
- Umbilical cord blood
NGS +
[Sanger]
Loci
Gen
| Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
|---|---|---|---|---|
| AMH | 1683 | NM_000479.5 | AR | |
| AMHR2 | 1722 | NM_020547.3 | AR | |
| AR | 2763 | NM_000044.6 | XLR | |
| ATRX | 7479 | NM_000489.6 | XL | |
| CDKN1C | 951 | NM_000076.2 | AD | |
| CHD7 | 8994 | NM_017780.4 | AD | |
| CUL4B | 2742 | NM_003588.4 | XLR | |
| CYB5A | 297 | NM_001914.4 | AR | |
| CYP11A1 | 1566 | NM_000781.3 | AR, AD | |
| CYP11B1 | 1512 | NM_000497.4 | AR | |
| CYP17A1 | 1527 | NM_000102.4 | AR | |
| CYP19A1 | 1512 | NM_031226.3 | AR | |
| CYP21A2 | 1488 | NM_000500.9 | AR | |
| DHCR7 | 1428 | NM_001360.3 | AR | |
| DHH | 1191 | NM_021044.4 | AR | |
| HSD17B3 | 933 | NM_000197.2 | AR | |
| HSD3B2 | 1119 | NM_000198.4 | AR | |
| LHCGR | 2100 | NM_000233.4 | AD, AR | |
| MAMLD1 | 2325 | NM_005491.5 | XLR | |
| MAP3K1 | 4539 | NM_005921.2 | AD | |
| NR0B1 | 1413 | NM_000475.5 | XL | |
| NR5A1 | 1386 | NM_004959.5 | AD, AR | |
| POR | 2043 | NM_001395413.1 | AR | |
| RPL10 | 651 | NM_006013.5 | XLR | |
| RSPO1 | 792 | NM_001038633.4 | AR | |
| SAMD9 | 4770 | NM_017654.4 | AD | |
| SGPL1 | 1721 | NM_003901.4 | XLR | |
| SOX10 | 1401 | NM_006941.4 | AD | |
| SOX9 | 1530 | NM_000346.4 | AD | |
| SRD5A2 | 764 | NM_000348.4 | AR | |
| SRY | 615 | NM_003140.3 | YL | |
| STAR | 858 | NM_000349.3 | AR | |
| TOE1 | 1488 | NM_025077.4 | AR | |
| TSPYL1 | 1314 | NM_003309.4 | AR | |
| WT1 | 1569 | NM_024426.6 | AD, SMu | |
| AKR1C2 | 420 | NM_001354.6 | AR | |
| AKR1C4 | 972 | NM_001818.5 | AR | |
| ANOS1 | 2043 | NM_000216.4 | XLR | |
| ARL6 | 561 | NM_177976.3 | AR | |
| B3GLCT | 1497 | NM_194318.4 | AR | |
| BBS1 | 1782 | NM_024649.5 | AR, digenisch | |
| BBS10 | 2172 | NM_024685.4 | AR | |
| BBS12 | 2133 | NM_152618.3 | AR | |
| BBS2 | 2166 | NM_031885.5 | AR | |
| BBS4 | 1560 | NM_033028.5 | AR | |
| BBS5 | 1026 | NM_152384.3 | AR | |
| BBS7 | 2148 | NM_176824.3 | AR | |
| BBS9 | 2664 | NM_198428.3 | AR | |
| CBX2 | 1599 | NM_005189.3 | AR | |
| CILK1 | 1899 | NM_014920.5 | AR | |
| DCAF17 | 1563 | NM_025000.4 | AR | |
| DHCR24 | 1551 | NM_014762.4 | AR | |
| DMRT1 | 1122 | NM_021951.3 | AD | |
| DYNC2H1 | 12945 | NM_001080463.2 | AR, digenisch | |
| DYNC2I1 | 3201 | NM_018051.5 | AR | |
| FEZF1 | 1428 | NM_001024613.4 | AR | |
| FGF8 | 735 | NM_033163.5 | AD | |
| FGFR1 | 2469 | NM_023110.3 | AR | |
| FGFR2 | 2466 | NM_000141.5 | AD | |
| FOXL2 | 1131 | NM_023067.4 | AD | |
| FRAS1 | 12039 | NM_025074.7 | AR | |
| FREM2 | 9510 | NM_207361.6 | AR | |
| FSHB | 390 | NM_000510.4 | AR | |
| GATA4 | 1329 | NM_002052.5 | AD | |
| GLI2 | 4761 | NM_005270.5 | AD | |
| GNRH1 | 291 | NM_000825.3 | AR | |
| GNRHR | 987 | NM_000406.3 | AR | |
| GRIP1 | 3231 | NM_021150.4 | AR | |
| HAMP | 255 | NM_021175.4 | AR | |
| HARS2 | 1521 | NM_012208.4 | AR | |
| HCCS | 807 | NM_005333.5 | XL | |
| HOXA13 | 1167 | NM_000522.5 | AD | |
| IL17RD | 2220 | NM_017563.5 | AR | |
| INSL3 | 474 | NM_005543.4 | AD | |
| KAT6B | 6222 | NM_012330.4 | AD | |
| KISS1R | 1197 | NM_032551.5 | AR | |
| KLB | 3135 | NM_175737.4 | AD | |
| LHB | 426 | NM_000894.3 | AR | |
| LHX1 | 1221 | NM_005568.5 | AD | |
| LHX4 | 1173 | NM_033343.4 | AD | |
| LZTFL1 | 900 | NM_020347.4 | AR | |
| MKKS | 1713 | NM_018848.3 | AR | |
| MKS1 | 1680 | NM_017777.4 | AR | |
| NEK1 | 3777 | NM_012224.4 | AR | |
| NSMF | 1587 | NM_015537.5 | AD | |
| PROK2 | 390 | NM_001126128.2 | AD, AR | |
| PROKR2 | 1155 | NM_144773.4 | AD, AR | |
| PROP1 | 681 | NM_006261.5 | AR | |
| ROR2 | 2832 | NM_004560.4 | AD, AR | |
| SALL1 | 3975 | NM_002968.3 | AD | |
| SDCCAG8 | 2142 | NM_006642.5 | AR | |
| SETBP1 | 4791 | NM_015559.3 | AD, SMu | |
| SLC29A3 | 1428 | NM_018344.6 | AR | |
| SLC40A1 | 1716 | NM_014585.6 | AD | |
| SOX2 | 954 | NM_003106.4 | AD | |
| SOX3 | 1341 | NM_005634.3 | XL | |
| SPECC1L | 3354 | NM_015330.6 | AD | |
| TAC3 | 366 | NM_013251.4 | AR | |
| TACR3 | 1398 | NM_001059.3 | AR | |
| TFR2 | 2406 | NM_003227.4 | AR | |
| TMEM67 | 2988 | NM_153704.6 | AR | |
| TTC8 | 1518 | NM_198309.3 | AR | |
| WDR11 | 3675 | NM_018117.12 | AD | |
| WNT4 | 1056 | NM_030761.5 | AD, AR | |
| WNT5A | 1143 | NM_003392.7 | AD | |
| ZFPM2 | 3456 | NM_012082.4 | AD |
Informations about the disease
DSD are rarely present prenatally, very complex conditions, management should be directed by highly specialised teams to allow consideration of all aspects of diagnosis, treatment + ethical issues. Female fetus (clitoromegaly with normal labia). Male fetus (micropenis, hypospadias, undescended testes, bifid scrotum). Associated abnormalities: Chromosomal, mainly trisomy 13, triploidy, 13q syndrome, in a few cases. The condition is commonly associated with genetic syndromes (Smith-Lemli-Opitz + WAGR syndromes), other defects, mainly facial clefts + cardiac defects are often found.
- Alias: Prenatal disorders of sex determination + differentiation
- Allelic Premature ovarian failure 3 (FOXL2)
- Allelic: Adrenocortical insufficiency (NR5A1)
- Allelic: Beckwith-Wiedemann syndrome (CDKN1C)
- Allelic: Congenital heart defects, multiple types, 4 (NR2F2)
- Allelic: Craniosynostosis 3 (TCF12)
- Allelic: Encephalitis/encephalopathy, mild, with reversible myelin vacuolization (MYRF)
- Allelic: Hemochromatosis, type 4 (SLC40A1)
- Allelic: Histiocytosis-lymphadenopathy plus syndrome (SLC29A3)
- Allelic: Hypospadias 1, XL (AR)
- Allelic: Neurodevelopmental disorder, brain anomalies with/-out vertebral/cardiac anomalies (DHX37)
- Allelic: Short-rib thoracic dysplasia 3 with/-out polydactyly (DYNC2H1)
- Allelic: Short-rib thoracic dysplasia 3 with/-out polydactyly (DYNC2I1)
- 17,20-lyase deficiency, isolated (CYP17A1)
- 17-alpha-hydroxylase/17,20-lyase deficiency (CYP17A1)
- 46,XX sex reversal 5 (NR2F2)
- 46XX sex reversal 1 (SRY)
- 46XX sex reversal 4 (NR5A1)
- 46XY partial gonadal dysgenesis, with minifascicular neuropathy (DHH)
- 46XY sex reversal 1 (SRY)
- 46XY sex reversal 11 (DHX37)
- 46XY sex reversal 2, dosage-sensitive (NR0B1)
- 46XY sex reversal 3 (NR5A1)
- 46XY sex reversal 5 (CBX2)
- 46XY sex reversal 6 (MAP3K1)
- 46XY sex reversal 7 (DHH)
- 46XY sex reversal 8 (AKR1C2)
- 46XY sex reversal 8, modifier of (AKR1C4)
- 46XY sex reversal 9 (ZFPM2)
- Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency (CYP11B1)
- Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency (CYP21A2)
- Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency (HSD3B2)
- Adrenal hypoplasia, congenital (NR0B1)
- Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete (CYP11A1)
- Aldosteronism, glucocorticoid-remediable (CYP11B1)
- Androgen insensitivity (AR)
- Androgen insensitivity, partial, with/-out breast cancer (AR)
- Antley-Bixler syndrome with genital anomalies + disordered steroidogenesis (POR)
- Aromatase deficiency (CYP19A1)
- Aromatase excess syndrome (CYP19A1)
- Bardet-Biedl s. (ARL6, BBS1, 10, 12, 2, 4, 5, 7, 9, LZTFR1, MKKS, MKS1, SDCCAG8, TMEM67, TTC()
- Beare-Stevenson cutis gyrata syndrome (FGFR2)
- Blepharophimosis, epicanthus inversus + ptosis, type 1 + 2 (FOXL2)
- CHARGE syndrome (CHD7)
- Campomelic dysplasia with autosomal sex reversal (SOX9)
- Cardiac-urogenital syndrome (MYRF)
- Cong. anomalies of kidney + urinary tract +/- hearing loss, abnormal ears/developmental delay (PBX1)
- Cryptorchidism INSL3)
- Culler-Jones syndrome (GLI2)
- Denys-Drash syndrome (WT1)
- Desmosterolosis (DHCR24)
- Disordered steroidogenesis due to cytochrome P450 oxidoreductase (POR)
- Endocrine-cerebroosteodysplasia (CILK1)
- Fraser syndrome 1 (FRAS1)
- Fraser syndrome 2 (FREM2)
- Fraser syndrome 3 (GRIP1)
- Frasier syndrome (WT1)
- Genitopatellar syndrome )KAT6B)
- Genitourinary and/or brain malformation syndrome (PPP1R12A)
- Glucocorticoid resistance (NR3C1)
- Guttmacher syndrome (HOXA13)
- Hand-foot-uterus syndrome (HOXA13)
- Hemochromatosis, type 3 (TFR2)
- Hydranencephaly with abnormal genitalia (ARX)
- Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency (CYP21A2)
- Hypogonadotropic hypogonadism 1 with/-out anosmia; Kallmann syndrome 1 (ANOS1)
- Hypogonadotropic hypogonadism 10 with/-out anosmia (TAC3)
- Hypogonadotropic hypogonadism 12 with/-out anosmia (GNRH1)
- Hypogonadotropic hypogonadism 14 with/-out anosmia (WDR11)
- Hypogonadotropic hypogonadism 17 with/-out anosmia (SPRY4)
- Hypogonadotropic hypogonadism 18 with/-out anosmia (IL17RD)
- Hypogonadotropic hypogonadism 2 with/-out anosmia (FGFR1)
- Hypogonadotropic hypogonadism 22, with/-out anosmia (FEZF1)
- Hypogonadotropic hypogonadism 23 with/-out anosmia (LHB)
- Hypogonadotropic hypogonadism 24 without anosmia (FSHB)
- Hypogonadotropic hypogonadism 26 with/-out anosmia (TCF12)
- Hypogonadotropic hypogonadism 3 with/-out anosmia (PROKR2)
- Hypogonadotropic hypogonadism 4 with/-out anosmia (PROK2)
- Hypogonadotropic hypogonadism 5 with/-out anosmia (CHD7)
- Hypogonadotropic hypogonadism 6 with/-out anosmia (FGF8)
- Hypogonadotropic hypogonadism 7 without anosmia (GNRHR)
- Hypogonadotropic hypogonadism 8 with/-out anosmia (KISS1R)
- Hypogonadotropic hypogonadism 9 with/-out anosmia (NSMF)
- Hypogonadotropic hypogonadism []panelapp] (HAMP)
- Hypospadias 2, XL (MAMLD1)
- Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia (PAX8)
- IMAGE syndrome (CDKN1C)
- Intellectual developmental disorder, XL, syndromic, 35 (RPL10)
- Leydig cell hypoplasia with hypergonadotropic hypogonadism (LHCGR)
- Leydig cell hypoplasia with pseudohermaphroditism (LHCGR)
- Linear skin defects with multiple congenital anomalies 1 (HCCS)
- Lipoid adrenal hyperplasia (STAR)
- Luteinizing hormone resistance, female (LHCGR)
- MIRAGE syndrome (SAMD9)
- Meacham syndrome (WT1)
- Mental retardation, XL, syndromic 15 [Cabezas type] (CUL4B)
- Mental retardation-hypotonic facies syndrome, XL (ATRX)
- Methemoglobinemia and ambiguous genitalia (CYB5A)
- Microcephaly, facial dysmorphism, renal agenesis + ambiguous genitalia syndrome (CTU2)
- Microphthalmia, syndromic 3 (SOX2)
- Mullerian aplasia and hyperandrogenism (WNT4)
- Nephrotic syndrome, type 14 (SSGPL1)
- Nivelon-Nivelon-Mabille [chondrodysplasia-pseudohermaphroditism] syndrome (HHAT)
- Normosmic IHH, idiopathic Hypogonadotropic hypogonadism [panelapp] (CCDC141)
- Opitz GBBB syndrome, type II (SECC1L)
- Ovarian dysgenesis 8 (ESR2)
- PCWH syndrome (SOX10)
- Palmoplantar hyperkeratosis + true hermaphroditism (RSPO1)
- Palmoplantar hyperkeratosis with squamous cell carcinoma of skin + sex reversal (RSPO1)
- Panhypopituitarism, XL (SOX3)
- Perrault syndrome 2 (HARS2)
- Persistent Mullerian duct syndrome, type I (AMH)
- Persistent Mullerian duct syndrome, type II (AMHR2)
- Peters-plus syndrome (B3GLCT)
- Pituitary hormone deficiency, combined, 2 (PROP1)
- Pituitary hormone deficiency, combined, 4 (LHX4)
- Pontocerebellar hypoplasia, type 7 (TOE1)
- Precocious puberty, central, 1 (KISS1R)
- Proud syndrome (ARX)
- Pseudohermaphroditism, male, with gynecomastia (HSD17B3)
- Pseudovaginal perineoscrotal hypospadias (SRD5A2)
- Robinow syndrome, AD 1 (WNT5A)
- Robinow syndrome, AR (ROR2)
- SERKAL syndrome (WNT4)
- Schinzel-Giedion midface retraction syndrome (SETBP1)
- Short-rib thoracic dysplasia 6 with/-out polydactyly (NEK1)
- Smith-Lemli-Opitz syndrome (DHCR7)
- Sudden infant death with dysgenesis of the testes syndrome (TSPYL1)
- Testicular anomalies with or without congenital heart disease (GATA4)
- Townes-Brocks syndrome 1 (SALL1)
- Waardenburg syndrome, type 2E, with/-out neurologic involvement (SOX10)
- Waardenburg syndrome, type 4C (SOX10)
- Woodhouse-Sakati syndrome (DCAF17)
- AD
- AR
- SMu
- XL
- XLR
- YL
- digenisch
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.